Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alexion's Defensive Play Poised To Pay Off

Executive Summary

The company's long-acting C5 complement inhibitor ALXN1210 demonstrated non-inferiority to Soliris in a Phase III trial, which should help the company defend against anticipated competition to its blockbuster franchise.

Advertisement

Related Content

Alexion Continues Pipeline Rebuilding With $400m Takeout Of Syntimmune
Keeping Track: Bristol Tests US FDA’s TMB Tolerance, Celltrion Resubmits Herceptin Biosimilar, Nocdurna Approved At Last
Keeping Track: Bristol Tests US FDA’s TMB Tolerance, Celltrion Resubmits Herceptin Biosimilar, Nocdurna Approved At Last
Alexion Seizes On New Soliris Indication, Business Development For Growth
Alexion Restructuring Deemed A Necessary Evil
Alexion CEO Hantson Tasked With Kicking Growth Momentum Into Gear
Alexion’s Investigation Reveals ‘Inappropriate’ Conduct, Nothing Illegal

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100577

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel